BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34529150)

  • 1. [Technology assessment of digital health applications for reimbursement decisions].
    Jeindl R; Wild C
    Wien Med Wochenschr; 2024 Mar; 174(3-4):44-52. PubMed ID: 34529150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic HTA for digital health solutions: opportunities and challenges for patient-centered evaluation.
    Brönneke JB; Herr A; Reif S; Stern AD
    Int J Technol Assess Health Care; 2023 Nov; 39(1):e72. PubMed ID: 37973549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The German Fast Track Toward Reimbursement of Digital Health Applications: Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes.
    Schliess F; Affini Dicenzo T; Gaus N; Bourez JM; Stegbauer C; Szecsenyi J; Jacobsen M; Müller-Wieland D; Kulzer B; Heinemann L
    J Diabetes Sci Technol; 2024 Mar; 18(2):470-476. PubMed ID: 36059268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How robust are studies of currently permanently included digital health applications (DiGA)? Methodological quality of studies demonstrating positive health care effects of DiGA].
    Kolominsky-Rabas PL; Tauscher M; Gerlach R; Perleth M; Dietzel N
    Z Evid Fortbild Qual Gesundhwes; 2022 Dec; 175():1-16. PubMed ID: 36437182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Market access and value-based pricing of digital health applications in Germany.
    Gensorowsky D; Witte J; Batram M; Greiner W
    Cost Eff Resour Alloc; 2022 Jun; 20(1):25. PubMed ID: 35698135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis.
    Mäder M; Timpel P; Schönfelder T; Militzer-Horstmann C; Scheibe S; Heinrich R; Häckl D
    BMC Health Serv Res; 2023 Apr; 23(1):369. PubMed ID: 37069592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The new approval process for the reimbursement of digital health applications (DiGA) from the perspective of the German statutory health insurance].
    Gregor-Haack J; Busse T; Hagenmeyer EG
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1220-1227. PubMed ID: 34459939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicians' Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study.
    Dahlhausen F; Zinner M; Bieske L; Ehlers JP; Boehme P; Fehring L
    JMIR Mhealth Uhealth; 2021 Nov; 9(11):e33012. PubMed ID: 34817385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital health applications from a government-regulated directory of reimbursable health apps in Germany-a systematic review for evidence and bias.
    Dittrich F; Mielitz A; Pustozerov E; Lawin D; von Jan U; Albrecht UV
    Mhealth; 2023; 9():35. PubMed ID: 38023782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are current clinical studies on artificial intelligence-based medical devices comprehensive enough to support a full health technology assessment? A systematic review.
    Farah L; Davaze-Schneider J; Martin T; Nguyen P; Borget I; Martelli N
    Artif Intell Med; 2023 Jun; 140():102547. PubMed ID: 37210155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological Frameworks and Dimensions to Be Considered in Digital Health Technology Assessment: Scoping Review and Thematic Analysis.
    Segur-Ferrer J; Moltó-Puigmartí C; Pastells-Peiró R; Vivanco-Hidalgo RM
    J Med Internet Res; 2024 Apr; 26():e48694. PubMed ID: 38598288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digital Health Applications in the Area of Mental Health.
    Schreiter S; Mascarell-Maricic L; Rakitzis O; Volkmann C; Kaminski J; Daniels MA
    Dtsch Arztebl Int; 2023 Nov; 120(47):797-803. PubMed ID: 37732500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment for digital technologies that manage chronic disease: a systematic review.
    von Huben A; Howell M; Howard K; Carrello J; Norris S
    Int J Technol Assess Health Care; 2021 May; 37(1):e66. PubMed ID: 34034851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ["Alternative study designs" for the evaluation of digital health applications - a real alternative?].
    Gensorowsky D; Lampe D; Hasemann L; Düvel J; Greiner W
    Z Evid Fortbild Qual Gesundhwes; 2021 Apr; 161():33-41. PubMed ID: 33642251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Practical use of digital health applications (DiGA) in internal medicine].
    Mittermaier M; Sina C; Richter JG; Raspe M; Stais P; Vehreschild J; Wolfrum S; Anthes C; Möckel M;
    Internist (Berl); 2022 Mar; 63(3):245-254. PubMed ID: 35037948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Digital health applications (DiGA) in the area of tension between progress and criticism : Discussion paper from the "Digital health" specialist group of the German Informatics Society].
    Schlieter H; Kählig M; Hickmann E; Fürstenau D; Sunyaev A; Richter P; Breitschwerdt R; Thielscher C; Gersch M; Maaß W; Reuter-Oppermann M; Wiese L
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Jan; 67(1):107-114. PubMed ID: 38086924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Problems and Barriers Related to the Use of Digital Health Applications: Protocol for a Scoping Review.
    Giebel GD; Speckemeier C; Abels C; Börchers K; Wasem J; Blase N; Neusser S
    JMIR Res Protoc; 2022 Apr; 11(4):e32702. PubMed ID: 35451979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Digital health applications (DiGA): assessment of reimbursability by means of the "DiGA Fast Track" procedure at the Federal Institute for Drugs and Medical Devices (BfArM)].
    Lauer W; Löbker W; Höfgen B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1232-1240. PubMed ID: 34529095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International practices in health technology assessment and public financing of digital health technologies: recommendations for Hungary.
    Mezei F; Horváth K; Pálfi M; Lovas K; Ádám I; Túri G
    Front Public Health; 2023; 11():1197949. PubMed ID: 37719722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.